Botanical medicines for the treatment of cancer: Rationale, overview of current data, and methodological considerations for Phase I and II trials

Cancer Investigation

Volumn 20, Issue 7-8, 2002, Pages 1069-1079

  Vickers, Andrew ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Botanical medicines; Cancer; Regulation; Research design

Indexed keywords

ANETHOLE; BAICALIN; BETA GLUCAN; COPTIS CHINENSIS EXTRACT; CYCLOPHOSPHAMIDE; EPHEDRA EXTRACT; ESSIAC; FLUOROURACIL; GLYCYRRHIZIC ACID; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; KAMPO; KRESTIN; LIMONENE; MITOMYCIN C; NONI EXTRACT; PACLITAXEL; PAU D ARCO EXTRACT; PC SPES; PLANT EXTRACT; SCHIZOPHYLLUM COMMUNE EXTRACT; SHI QUAN DA BU TANG; THYMOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN; XIAO CHAI HU TANG;

CANCER; CLINICAL TRIAL; DRUG ISOLATION; DRUG SYNTHESIS; GENETICS; GYNECOMASTIA; HERBAL MEDICINE; HUMAN; INSOMNIA; LIBIDO DISORDER; MASTALGIA; MOISTURE; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SOIL QUALITY; TEMPERATURE DEPENDENCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; PHYTOTHERAPY;

EID: 0036419057     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120005926     Document Type: Review

References (89)

1. Eisenberg, D.M.; Davis, R.B.; Ettner, S.L.; Appel, S.; Wilkey, S.; Van Rompay, M.; Kessler, R.C. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. J. Am. Med. Assoc. 1998, 280, 1569-1575.
2. Boon, H.; Stewart, M.; Kennard, M.A.; Gray, R.; Sawka, C.; Brown, J.B.; McWilliam, C.; Gavin, A.; Baron, R.A.; Aaron, D.; Haines Kamka, T. Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions. J. Clin. Oncol. 2000, 18 (13), 2515-2521.
3. Richardson, M.A.; Sanders, T.; Palmer, J.L.; Greisinger, A.; Singletary, S.E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J. Clin. Oncol. 2000, 18 (13), 2505-2514.
4. Kao, G.D.; Devine, P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000, 88 (3), 615-619.
5. Small, E.J.; Frohlich, M.W.; Bok, R.; Shinohara, K.; Grossfeld, G.; Rozenblat, Z.; Kelly, W.K.; Corry, M.; Reese, D.M. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J. Clin. Oncol. 2000, 18 (21), 3595-3603.
6. Pisters, K.M.; Newman, R.A.; Coldman, B.; Shin, D.M.; Khuri, F.R.; Hong, W.K.; Glisson, B.S.; Lee, J.S. Phase I trial of oral green tea extract in adult patients with solid tumors. J. Clin. Oncol. 2001, 19 (6), 1830-1838.
7. http://nccam.nih.gov/nccam/fi/concepts/nov2000/herbal.html (accessed 4/20/2001).
8. Cragg, G.M.; Newman, D.J.; Weiss, R.B. Coral reefs, forests, and thermal vents: The worldwide exploration of nature for novel antitumor agents. Semin. Oncol. 1997, 24 (2), 156-163.
9. Cragg, G.M.; Newman, D.J. Discovery and development of antineoplastic agents from natural sources. Cancer Investig. 1999, 17 (2), 153-163.
10. Hosoya, E. Scientific evaluation of kampo prescriptions using modern technology. In Recent Advances in Pharmacology of Kampo (Japanese Herbal) Medicines; Hosoya, E., Yamamura, Y., Eds.; Excerpta Medica: Amsterdam, 1988.
11. Okita, K.; Li, Q.; Murakamio, T.; Takahashi, M. Antigrowth effects with components of Sho-saiko-to (TJ-9) on cultured human hepatoma cells. Eur. J. Cancer Prev. 1993, 2 (2), 169-175.
12. Yano, H.; Mizoguchi, A.; Fukuda, K.; Haramaki, M.; Ogasawara, S.; Momosaki, S.; Kojiro, M. The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res. 1994, 54 (2), 448-454.
13. Kaneko, M.; Kawakita, T.; Tauchi, Y.; Saito, Y.; Suzuki, A.; Nomoto, K. Augmentation of NK activity after oral administration of a traditional chinese medicine, Xiao-chai-hu-tang (Shosaiko-to). Immunopharmacol. Immunotoxicol. 1994, 16 (1), 41-53.
14. Li, X.; Tong, W.; Bornmann, W.; Schwartz, G.K. Huanglian Chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 inhibiting CDC2 kinase activity in human cancer cells. Mol. Pharmacol. 2000, 58 (6), 1287-1293.
15. Hiwasa, T.; Arase, Y.; Chen, Z.; Kita, K.; Umezawa, K.; Ito, H.; Suzuki, N. Stimulation of ultraviolet-induced apoptosis of human fibroblast Uvr-1 cells by tyrosine kinase inhibitors. FEBS Lett. 1999, 444 (2-3), 173-176.
16. Hirazumi, A.; Furusawa, E. An immunomodulatory polysaccharide-rich substance from the fruit juice of morinda citrifolia (noni) with antitumour activity. Phytother. Res. 1999, 13 (5), 380-387.
17. Darzynkiewicz, Z.; Traganos, F.; Wu, J.M.; Chen, S. Chinese herbal mixture PC SPES in treatment of prostate cancer (Review). Int. J. Oncol. 2000, 17 (4), 729-736.
18. Vickers, A.; Zollman, C. ABC of complementary medicine: Herbal medicine. Br. Med. J. 1999, 319 (7216), 1050-1053.
19. Opdyke, D.L. Inhibition of sensitization reactions induced by certain aldehydes. Food Cosmet. Toxicol. 1976, 14 (3), 197-198.
20. Mizoguchi, Y.; Kawada, N.; Ichikawa, Y.; Tanabe, I.; Mizuno, M.; Tomekawa, K.; Hasegawa, I.; Morisawa, S.; Yamamoto, S. The Effects of Sho-saiko-to on interluekin production I production by hepatic sinusoidal endothelial cells. J. Med. Pharm. Soc. 1989, 6, 172-176.
21. http://cbc.ca/consumers/market/files/health/herbdrugs. html (accessed 08/24/01).
22. Lazarowych, N.J.; Pekos, P. Use of fingerprinting and marker compounds for identification and standardization of botanical drugs: Strategies for applying pharmaceutical HPLC analysis to herbal products. Drug Inf. J. 1998, 32, 497-512.
23. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's Wort. Lancet 2000, 355 (9203), 547-548.
24. Miller, L.G. Herbal Medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Int. Med. 1998, 158 (20), 2200-2211.
25. Ito, H.; Shimura, K. Effects of a blended chinese medicine, Xiao-chai-hu-tang, on Lewis lung carcinoma growth and inhibition of lung metastasis, with special reference to macrophage activation. Jpn. J. Pharmacol. 1986, 41 (3), 307-314.
26. Kato, M.; Liu, W.; Yi, H.; Asai, N.; Hayakawa, A.; Kozaki, K.; Takahashi, M.; Nakashima, I. The herbal medicine Sho-saiko-to inhibits growth and metastasis of malignant melanoma primarily developed in rettransgenic mice. J. Investig. Dermatol. 1998, 111 (4), 640-644.
27. Yamashiki, M.; Kosaka, Y.; Nishimura, A.; Takase, K.; Ichida, F. Efficacy of a herbal medicine "Sho-saiko-to" on the improvement of impaired cytokine production of peripheral blood mononuclear cells in patients with chronic viral hepatitis. J. Clin. Lab. Immunol. 1992, 37 (3), 111-121.
28. Oka, H.; Yamamoto, S.; Kuroki, T.; Harihara, S.; Marumo, T.; Kim, S.R.; Monna, T.; Kobayashi, K.; Tango, T. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995, 76 (5), 743-749.
29. Ohnishi, Y.; Fujii, H.; Hayakawa, Y.; Sakukawa, R.; Yamaura, T.; Sakamoto, T.; Tsukada, K.; Fujimaki, M.; Nunome, S.; Komatsu, Y.; Saiki, I. Oral administration of a Kampo (Japanese Herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn. J. Cancer Res. 1998, 89 (2), 206-213.
30. Onishi, Y.; Yamaura, T.; Tauchi, K.; Sakamoto, T.; Tsukada, K.; Nunome, S.; Komatsu, Y.; Saiki, I. Expression of the anti-metastatic effect induced by Juzen-taiho-to is based on the content of Shimotsu-to constituents. Biol. Pharm. Bull. 1998, 21, 761-765.
31. Kiyohara, H.; Matsumoto, T.; Komatsu, Y.; Yamada, H. Protective effect of oral administration of a pectic polysaccharide fraction from a Kampo (Japanese Herbal) medicine "Juzen-taiho-to" on adverse effects of Cis-Diaminedichloroplatinum. Planta Med. 1995, 61, 531-534.
32. Sugiyama, K.; Ueda, H.; Ichio, Y.; Yokota, M. Improvement of cisplatin toxicity and lethality by Juzen-taiho-to in mice. Biol. Pharm. Bull. 1995, 18, 53-58.
33. DiPaola, R.S.; Zhang, H.; Lambert, G.H.; Meeker, R.; Licitra, E.; Rafi, M.M.; Zhu, B.T.; Spaulding, H.; Goodin, S.; Toledano, M.B.; Hait, W.N.; Gallo, M.A. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N. Engl. J. Med. 1998, 339 (12), 785-791.
34. de la Taille, A.; Buttyan, R.; Hayek, O.; Bagiella, E.; Shabsigh, A.; Burchardt, M.; Burchardt, T.; Chopin, D.K.; Katz, A.E. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J. Urol. 2000, 164 (4), 1229-1234.
35. Oh, W.K.; George, D.J.; Hackmann, K.; Manola, J.; Kantoff, P.W. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001, 57 (1), 122-126.
36. Pfeifer, B.L.; Pirani, J.F.; Hamann, S.R.; Klippel, K.F. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. Br. J. Urol. Int. 2000, 85 (4), 481-485.
37. Adachi, K.; Nanba, H.; Kuroda, H. Potentiation of host-mediated antitumor activity in mice by beta-glucan obtained from grifola frondosa (Maitake). Chem. Pharm. Bull. (Tokyo) 1987, 35 (1), 262-270.
38. Suzuki, I.; Hashimoto, K.; Oikawa, S.; Sato, K.; Osawa, M.; Yadomae, T. Antitumor and immunomodulating activities of a beta-glucan obtained from liquid-cultured grifola frondosa. Chem. Pharm. Bull. (Tokyo) 1989, 37 (2), 410-413.
39. Suzuki, I.; Hashimoto, K.; Ohno, N.; Tanaka, H.; Yadomae, T. Immunomodulation by orally administered beta-glucan in mice. Int. J. Immunopharmacol. 1989, 11 (7), 761-769.
40. Abel, G.; Czop, J.K. Stimulation of human monocyte beta-glucan receptors by glucan particles induces production of TNF-alpha and IL-1 beta. Int. J. Immunopharmacol. 1992, 14 (8), 1363-1373.
41. Kato, M.; Hirose, K.; Hakozaki, M. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol. Immunother. 1995, 40, 152-156.
42. Kano, Y.; Kakuta, H.; Hashimoto, J. Effect of sizofiran on regional lymph nodes in patients with head and neck cancer. Biotherapy 1996, 9 (4), 257-262.
43. Yamada, Y.; Nanba, H.; Kuroda, H. Antitumor effect of orally administered extracts from fruit body of grifola frondosa (Maitake). Chemotherapy 1990, 38 (8), 790-796.
44. Hishida, I.; Nanba, H.; Kuroda, H. Antitumor activity exhibited by orally administered extract from fruit body of grifola frondosa (Maitake). Chem. Pharm. Bull. (Tokyo) 1988, 36 (5), 1819-1827.
45. Kobayashi, H.; Matsunaga, K.; Oguchi, Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: An overview. Cancer Epidemiol. Biomark. Prev. 1995, 4 (3), 275-281.
46. Abe, S.; Tsubouchi, J.; Takahashi, K.; Yamazaki, M.; Mizuno, D. Combination therapy of murine tumors with lentinan plus lipopolysaccharide plus cyclophosphamide. Gann 1982, 73 (6), 961-967.
47. Kurashige, S.; Akuzawa, Y.; Endo, F. Effects of lentinus edodes, grifola frondosa and pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-Butyl-N-butanolnitrosoamine. Immunopharmacol. Immunotoxicol. 1997, 19 (2), 175-183.
48. Nanba, H. Activity of Maitake D-fraction to inhibit carcinogenesis and metastasis. Ann. N. Y. Acad. Sci. 1995, 768, 243-245.
49. Borchers, A.T.; Stem, J.S.; Hackman, R.M.; Keen, C.L.; Gershwin, M.E. Mushrooms, tumors, and immunity. Proc. Soc. Exp. Biol. Med. 1999, 221 (4), 281-293.
50. Kanoh, T.; Saito, K.; Matsunaga, K.; Oguchi, Y.; Taniguchi, N.; Endoh, H.; Yoshimura, M.; Fujii, T.; Yoshikumi, C. Enhancement of the antitumor effect by the Concurrent Use of a Monoclonal Antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line. In Vivo 1994, 8 (2), 241-245.
51. Niimoto, M.; Hattori, T.; Tamada, R.; Sugimachi, K.; Inokuchi, K.; Ogawa, N. Postoperative adjuvant immunochemotherapy with mitomycin c, futraful, and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn. J. Surg. 1988, 18 (6), 681-686.
52. Nakazato, H.; Koike, A.; Saji, S.; Ogawa, N.; Sakamoto, J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. The Lancet 1994, 343, 1122-1126.
53. Ogoshi, K.; Satou, H.; Isono, K.; Mitomi, T.; Endoh, M.; Sugita, M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am. J. Clin. Oncol. 1995, 18 (3), 216-222.
54. Toi, M.; Hattori, T.; Akagi, M.; Inokuchi, K.; Orita, K.; Sugimachi, K.; Dohi, K.; Nomura, Y.; Monden, Y.; Hamada, Y. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the adjuvant chemoendocrine therapy for breast cancer organization. Cancer 1992, 70 (10), 2475-2483.
55. Iino, Y.; Yokoe, T.; Maemura, M.; Horiguchi, J.; Takei, H.; Ohwada, S.; Morishita, Y. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 1995, 15 (6B), 2907-2911.
56. Ohno, R.; Yamada, K.; Masaoka, T.; Ohshima, T.; Amaki, I.; Hirota, Y.; Horikoshi, N.; Horiuchi, A.; Imai, K.; Kimura, I. A Randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol. Immunother. 1984, 18, 149-154.
57. Fujimoto, S.; Furue, H.; Kimura, T.; Kondo, T.; Orita, K.; Taguchi, T.; Yoshida, K.; Ogawa, N. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer - A randomized controlled trial. Jpn. J. Surg. 1984, 14 (4), 286-292.
58. Fujimoto, S.; Furue, H.; Kimura, T.; Kondo, T.; Orita, K.; Taguchi, T.; Yoshida, K.; Ogawa, N. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: A randomised controlled study. Eur. J. Cancer 1991, 27 (9), 1114-1118.
59. Okamura, K.; Suzuki, M.; Chihara, T.; Fujiwara, A.; Fukuda, T.: Goto, S.; Ichinohe, K.; Jimi, S.; Kasamatsu, T.; Kawai, N. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy 1989, 1 (2), 103-107.
60. Noda, K.; Takeuchi, S.; Yajima, A.; Akiya, K.; Kasamatsu, T.; Tomoda, Y.; Ozawa, M.; Sekiba, K.; Sugimori, H.; Hashimoto, S. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: A randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer. Jpn. J. Clin. Oncol. 1992, 22 (1), 17-25.
61. Torisu, M.; Hayashi, Y.; Ishimitsu, T.; Fujimura, T.; Iwasaki, K.; Katano, M.; Yamamoto, H.; Kimura, Y.; Takesue, M.; Kondo, M. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol. Immunother. 1990, 31, 261-268.
62. Mitomi, T.; Tsuchiya, S.; Iijima, N.; Aso, K.; Suzuki, K.; Nishiyama, K.; Amano, T.; Takahashi, T.; Murayama, N.; Oka, H. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis. Colon Rectum 1992, 35 (2), 123-130.
63. Kobayashi, Y.; Yamashita, Y.; Fujii, N.; Takaboshi, K.; Kawakami, T.; Kawamura, M.; Mizukami, T.; Nakano, H. Inhibitors of DNA topoisomerase I and II isolated from the coptis rhizomes. Planta Med. 1995, 61 (5), 414-418.
64. Kohlmeier, L.; Weterings, K.G.; Steck, S.: Kok, F.J. Tea and cancer prevention: An evaluation of the epidemiologic literature. Nutr. Cancer 1997, 27 (1), 1-13.
65. Ji, B.T.; Chow, W.H.; Hsing, A.W.; McLaughlin, J.K.; Dai, Q.; Gao, Y.T.; Blot, W.J.; Fraumeni, J.F., Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 1997, 70 (3), 255-258.
66. Hirose, M.; Hoshiya, T.; Akagi, K.; Takahashi, S.; Hara, Y.; Ito, N. Effects of green tea catechins in a rat multiorgan carcinogenesis model. Carcinogenesis 1993, 14 (8), 1549-1553.
67. Hirose, M.; Takahashi, S.; Ogawa, K.; Futakuchi, M.; Shirai, T.; Shibutani, M.; Uneyama, C.; Toyoda, K.; Iwata, H. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett. 1999, 143 (2), 173-178.
68. Yang, G.Y.; Liao, J.; Kim, K.; Yurkow, E.J.; Yang, C.S. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998, 19 (4), 611-616.
69. Chen, Z.P.; Schell, J.B.; Ho, C.T.; Chen, K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998, 129 (2), 173-179.
70. Kelloff, G.J.; Crowell, J.A.; Steele, V.E.; Lubet, R.A.; Malone, W.A.; Boone, C.W.; Kopelovich, L.; Hawk, E.T.; Lieberman, R.; Lawrence, J.A.; Ali, I.; Viner, J.L.; Sigman, C.C. Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents. J. Nutr. 2000, 130 (2S Suppl.), 467S-471S.
71. Kaegi, E. Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. Can. Med. Assoc. J. 1998, 158 (7), 897-902.
72. Kleijnen, J.; Knipschild, P. Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1994, 1, 255-260.
73. McNamee, D. Mistletoe extract ineffective in melanoma (News). Lancet 1999, 354, 1101.
74. Steuer Vogt, M.K.; Bonkowsky, V.; Ambrosch, P.; Scholz, M.; Neiss, A.; Strutz, J.; Hennig, M.; Lenarz, T.; Arnold, W. The Effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur. J. Cancer. 2001, 37 (1), 23-31.
75. Lenartz, D.; Dott, U.; Menzel, J.; Schierholz, J.M.; Beuth, J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 2000, 20 (3B), 2073-2076.
76. http://www.go-symmetry.com/Noni.htm (accessed 08/04/00).
77. Hirazumi, A.; Furusawa, E.; Chou, S.C.; Hokama, Y. Anticancer activity of morinda citrifolia (Noni) on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Proc. West. Pharmacol. Soc. 1994, 37, 145-146.
78. da Consolacao, M.; Linardi, F.; de Oliveira, M.M.; Sampaio, M.R. A lapachol derivative active against mouse lymphocytic leukemia P-388. J. Med. Chem. 1975, 18 (11), 1159-1161.
79. Block, J.B.; Serpick, A.A.; Miller, W.; Wiernik, P.H. Early clinical studies with lapachol (NSC-11905). Cancer Chemother. Rep. 2 1974, 4 (4), 27-28.
80. Fornell, J.; Sundin, Y.; Lindhe, J. Effect of listerine on dental plaque and gingivitis. Scand. J. Dent. Res. 1975, 83, 18-23.
81. Melzig, M.; Teuscher, E. Investigations of the influence of essential oils and their main components on the adenosine uptake by cultivated endothelial cells. Planta Med. 1991, 57 (1), 41-42.
82. Ravid, U.; Putievsky, E. Carvacrol and thymol chemotypes of East Meditarranean wild labiatae herbs. In Progress in Essential Oil Research: Brunke, E.J., Ed.; Walter de Gryter: Berlin, 1986, 163-167.
83. Marotti, M. Effects of variety and ontogenic stage on the essential oil composition and biological activity of fennel (Foeniculum Vulgare Mill). J. Essential Oil Res. 1994, 6 (1), 57-62.
84. Linde, K.; Ramirez, G.; Mulrow, C.D.; Pauls, A.; Weidenhammer, W.; Melchart, D. St John's Wort for depression - An overview and meta-analysis of randomised clinical trials. Br. Med. J. 1996, 313 (7052), 253-258.
85. Chen, Z.P.; Schell, J.B.; Ho, C.T.; Chen, K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998, 129 (2), 173-179.
86. Linde, K.; Mulrow, C.D. St John's Wort for Depression (Cochrane Review). The Cochrane Library; Update Software: Oxford, 2000.
87. Hirose, M.; Hoshiya, T.; Akagi, K.; Takahashi, S.; Hara, Y.; Ito, N. Effects of green tea catechins in a rat multiorgan carcinogenesis model. Carcinogenesis 1993, 14 (8), 1549-1553.
88. Eisenhauer, E.A.; O'Dwyer, P.J.; Christian, M.; Humphrey, J.S. Phase I clinical trial design in cancer drug development. J. Clin. Oncol. 2000, 18 (3), 684-692.
89. Swerdlow, J.L. Rediscovering the roots of modem medicine. Global Health Environ. Monitor 2001, 9 (1), 1.